Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 03, 2016 12:00 ET | Source: Trillium Therapeutics Inc.

Trillium Presents Initial Data From Ongoing Study of TTI-621 in Patients With Advanced Hematologic Malignancies at the American Society of Hematology Annual Meeting

SAN DIEGO, CALIFORNIA--(Marketwired - Dec. 3, 2016) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TR), a clinical-stage immuno-oncology company developing innovative therapies for the...
November 29, 2016 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Announces Conference Call and Webcast on December 5th to Discuss TTI-621 Data Presented at ASH

TORONTO, ONTARIO--(Marketwired - Nov. 29, 2016) - Trillium Therapeutics Inc. (TSX:TR)(NASDAQ:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the...
November 10, 2016 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Reports Third Quarter 2016 Financial Results and Provides Corporate Update

TORONTO, ONTARIO--(Marketwired - Nov. 10, 2016) - Additional clinical data from TTI-621 Phase 1a trial to be presented at 2016 American Society of...
November 03, 2016 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Announces Investor and Scientific Presentation Schedule for Remainder of 2016

TORONTO, ONTARIO--(Marketwired - Nov. 3, 2016) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TR), a clinical stage immuno-oncology company developing innovative therapies for the...
November 02, 2016 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Advances TTI-621 Into Phase 1b Cohort Expansion Enrollment

TORONTO, ONTARIO--(Marketwired - Nov. 2, 2016) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TR), a clinical-stage immuno-oncology company developing innovative therapies for the...
August 31, 2016 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Introduces Industry Postdoctoral Fellowship Program

TORONTO, ONTARIO--(Marketwired - Aug. 31, 2016) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TR), a clinical stage immuno-oncology company developing innovative therapies for the...
August 23, 2016 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics to Present at Investor and Scientific Conferences in September

TORONTO, ONTARIO--(Marketwired - Aug. 23, 2016) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TR), a clinical stage immuno-oncology company developing innovative therapies for the...
August 17, 2016 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Receives FDA Clearance to Proceed With TTI-621 in Clinical Trial Targeting Solid Tumors and Mycosis Fungoides

TORONTO, ONTARIO--(Marketwired - Aug. 17, 2016) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TR), a clinical stage immuno-oncology company developing innovative therapies for the...
August 12, 2016 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Reports Second Quarter 2016 Financial Results

TORONTO, ONTARIO--(Marketwired - Aug. 12, 2016) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TR), a clinical stage immuno-oncology company developing innovative therapies for the...
June 07, 2016 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Announces Presentation on TTI-621 Immune Checkpoint Inhibitor Targeting CD47 at European Hematology Association 21st Annual Congress

TORONTO, ONTARIO--(Marketwired - June 7, 2016) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TR), a clinical stage immuno-oncology company developing innovative therapies for the...